This trial is testing the side effects of human lysozyme goat milk in preventing graft versus host disease for patients with blood cancer who are undergoing a donor stem cell transplant.
The primary treatment in this trial is Group A, which consists of conditioning, goat milk, transplant, and prophylaxis. This treatment is free for participants. There will be no placebo group in this trial, as all patients will receive the primary treatment. Group A has been previously approved by the FDA for a different condition.